Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma

Clinical Cancer Research

Volumn 17, Issue 15, 2011, Pages 4965-4974

  Kubo, Takafumi ^a   Toyooka, Shinichi ^a   Tsukuda, Kazunori ^a   Sakaguchi, Masakiyo ^a   Fukazawa, Takuya ^a   Soh, Junichi ^a   Asano, Hiroaki ^a   Ueno, Tsuyoshi ^a   Muraoka, Takayuki ^a   Yamamoto, Hiromasa ^a   Nasu, Yasutomo ^a   Kishimoto, Takumi ^b   Pass, Harvey I ^c   Matsui, Hideki ^a   Huh, Nam Ho ^a   Miyoshi, Shinichiro ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA ROSAI HOSPITAL   (Japan)

^c NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MICRORNA; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL MIGRATION; CELL MOTILITY; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; EPIGENETICS; GENE OVEREXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALIGNANT MESOTHELIOMA; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR SUPPRESSOR GENE;

CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DNA METHYLATION; HUMANS; MESOTHELIOMA; MICRORNAS; PLEURAL NEOPLASMS; RNA INTERFERENCE; TRANSFECTION;

EID: 79961015580     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-10-3040     Document Type: Article

References (44)

1. Spirtas R, Heineman EF, Bernstein L, Beebe GW, Keehn RJ, Stark A, et al. Malignant mesothelioma: attributable risk of asbestos exposure. Occup Environ Med 1994;51:804-11. (Pubitemid 24368130)
2. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408. (Pubitemid 41073959)
3. Cote RJ, Jhanwar SC, Novick S, Pellicer A. Genetic alterations of the p53 gene are a feature of malignant mesotheliomas. Cancer Res 1991;51:5410-6.
4. Metcalf RA, Welsh JA, Bennett WP, Seddon MB, Lehman TA, Pelin K, et al. p53 and Kirsten-ras mutations in human mesothelioma cell lines. Cancer Res 1992;52:2610-5.
5. Shimamura A, Fisher DE. p53 in life and death. Clin Cancer Res 1996;2:435-40. (Pubitemid 26099169)
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004;116:281-97.
7. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature 2005;435:834-8. (Pubitemid 40839735)
8. Garzon R, Calin GA, Croce CM. MicroRNAs in cancer. Annu Rev Med 2009;60:167-79.
9. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, et al. A microRNA component of the p53 tumour suppressor network. Nature 2007;447:1130-4. (Pubitemid 47014436)
10. Bommer GT, Gerin I, Feng Y, Kaczorowski AJ, Kuick R, Love RE, et al. p53-mediated activation of miRNA34 candidate tumor-suppressor genes. Curr Biol 2007;17:1298-307. (Pubitemid 47176893)
11. Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res 2007;67:8433-8. (Pubitemid 47437414)
12. Hermeking H. p53 enters the microRNA world. Cancer Cell 2007;12:414-8. (Pubitemid 350046413)
13. Murthy SS, Shen T, De Rienzo A, Lee WC, Ferriola PC, Jhanwar SC, et al. Expression of GPC3, an X-linked recessive overgrowth gene, is silenced in malignant mesothelioma. Oncogene 2000;19:410-6. (Pubitemid 30077342)
14. Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC, et al. 50 CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1995;1:686-92.
15. Saito Y, Liang G, Egger G, Friedman JM, Chuang JC, Coetzee GA, et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 2006;9:435-43. (Pubitemid 43832188)
16. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setién F, et al. Genetic unmasking of an epigenetically silenced microRNA in human cancer cells. Cancer Res 2007;67:1424-9. (Pubitemid 46383366)
17. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res 2008;68:4123-32.
18. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Körner H, et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008;7:2591-600.
19. Busacca S, Germano S, De Cecco L, Rinaldi M, Comoglio F, Favero F, et al. MicroRNA signature of malignant mesothelioma with potential diagnostic and prognostic implications. Am J Respir Cell Mol Biol 2010;42:312-9.
20. Guled M, Lahti L, Lindholm PM, Salmenkivi K, Bagwan I, Nicholson AG, et al. CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma -A miRNA microarray analysis. Genes Chromosomes Cancer 2009;48:615-23.
21. Pass HI, Goparaju C, Ivanov S, Donington J, Carbone M, Hoshen M, et al. hsa-miR-29c*is linked to the prognosis of malignant pleural mesothelioma. Cancer Res 2010;70:1916-24.
22. Toyooka S, Pass HI, Shivapurkar N, Fukuyama Y, Maruyama R, Toyooka KO, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-30. (Pubitemid 32769086)
23. Gandhi J, Zhang J, Xie Y, Soh J, Shigematsu H, Zhang W, et al. Alterations in genes of the EGFR signaling pathway and their relationship to EGFR tyrosine kinase inhibitor sensitivity in lung cancer cell lines. PLoS One 2009;4:e4576.
24. Ramirez RD, Sheridan S, Girard L, Sato M, Kim Y, Pollack J, et al. Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res 2004;64:9027-34. (Pubitemid 39665513)
25. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation- specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 1996;93:9821-6. (Pubitemid 26296693)
26. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One 2009;4:e6816.
27. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci U S A 1998;95:2509-14. (Pubitemid 28145972)
28. Hollstein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancers. Science 1991;253:49-53. (Pubitemid 21917115)
29. Prins JB, Williamson KA, Kamp MM, Van Hezik EJ, Van der Kwast TH, Hagemeijer A, et al. The gene for the cyclin-dependent-kinase-4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma. Int J Cancer 1998;75:649-53. (Pubitemid 28094115)
30. Sekido Y. Molecular biology of malignant mesothelioma. Environ Health Prev Med 2008;13:65-70.
31. Toyooka S, Kishimoto T, Date H. Advances in the molecular biology of malignant mesothelioma. Acta Med Okayama 2008;62:1-7. (Pubitemid 351463551)
32. Hopkins-Donaldson S, Belyanskaya LL, Simo&tild;es-Wüst AP, Sigrist B, Kurtz S, Zangemeister-Wittke U, et al. p53-induced apoptosis occurs in the absence of p14(ARF) in malignant pleural mesothelioma. Neoplasia 2006;8:551-9. (Pubitemid 44061310)
33. Gordon GJ, Rockwell GN, Jensen RV, Rheinwald JG, Glickman JN, Aronson JP, et al. Identification of novel candidate oncogenes and tumor suppressors in malignant pleural mesothelioma using large-scale transcriptional profiling. Am J Pathol 2005;166:1827-40. (Pubitemid 40734405)
34. Pataer A, Smythe WR, Yu R, Fang B, McDonnell T, Roth JA, et al. Adenovirus-mediated Bak gene transfer induces apoptosis in mesothelioma cell lines. J Thorac Cardiovasc Surg 2001;121:61-7. (Pubitemid 32105324)
35. Jagadeeswaran R, Ma PC, Seiwert TY, Jagadeeswaran S, Zumba O, Nallasura V, et al. Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Cancer Res 2006;66:352-61. (Pubitemid 43166042)
36. Aggarwal BB, Ichikawa H. Molecular targets and anticancer potential of indole-3-carbinol and its derivatives. Cell Cycle 2005;4:1201-15. (Pubitemid 41365390)
37. Frizelle SP, Kratzke MG, Carreon RR, Engel SC, Youngquist L, Klein MA, et al. Inhibition of both mesothelioma cell growth and Cdk4 activity following treatment with a TATp16INK4a peptide. Anticancer Res 2008;28:1-7.
38. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ 2003;10:431-42. (Pubitemid 36626355)
39. Soini Y, Kinnula V, Kaarteenaho-Wiik R, Kurttila E, Linnainmaa K, Paakko P. Apoptosis and expression of apoptosis regulating proteins bcl-2, mcl-1, bcl-X, and bax in malignant mesothelioma. Clin Cancer Res 1999;5:3508-15.
40. O'Kane SL, Pound RJ, Campbell A, Chaudhuri N, Lind MJ, Cawkwell L. Expression of bcl-2 family members in malignant pleural mesothelioma. Acta Oncol 2006;45:449-53. (Pubitemid 43884613)
41. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006;6:857-66. (Pubitemid 44629897)
42. Spizzo R, Nicoloso MS, Croce CM, Calin GA. SnapShot: microRNAs in cancer. Cell 2009;137:586-e1.
43. Chung KH, Hart CC, Al-Bassam S, Avery A, Taylor J, Patel PD, et al. Polycistronic RNA polymerase II expression vectors for RNA interference based on BIC/miR-155. Nucleic Acids Res 2006;34:e53.
44. Stegmeier F, Hu G, Rickles RJ, Hannon GJ, Elledge SJ. A lentiviral microRNA-based system for single-copy polymerase II-regulated RNA interference in mammalian cells. Proc Natl Acad Sci U S A 2005;102:13212-7. (Pubitemid 41325003)